Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | UGCG | Q16739 | 5/20 | 0.44 |
| ▸ | GBA2 | Q9HCG7 | 5/20 | 0.44 |
| ▸ | GBA1 | P04062 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | LCT | P09848 | 2/20 | 0.38 |
| ▸ | SI | P14410 | 2/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19437614 | 0.98 | KDM4E (0.47) | L3MBTL1TDP1KDM4EPOLBUGCG | |
| SCHEMBL16248683 | 0.95 | KDM4E (0.47) | L3MBTL1TDP1KDM4EPOLBUGCG | |
| SCHEMBL22912637 | 0.95 | KDM4E (0.47) | L3MBTL1TDP1KDM4EPOLBUGCG | |
| SCHEMBL16248689 | 0.93 | KDM4E (0.53) | L3MBTL1TDP1KDM4EPOLBUGCG | |
| SCHEMBL22747317 | 0.91 | UGCG (0.43) | L3MBTL1TDP1KDM4EPOLBUGCG | |
| SCHEMBL26510423 | 0.90 | KDM4E (0.50) | L3MBTL1TDP1KDM4EPOLBUGCG | |
| SCHEMBL22227353 | 0.89 | KDM4E (0.45) | L3MBTL1TDP1KDM4EPOLBUGCG | |
| SCHEMBL19437686 | 0.89 | KDM4E (0.51) | L3MBTL1TDP1KDM4EPOLBUGCG | |
| SCHEMBL17941033 | 0.88 | L3MBTL1 (0.53) | L3MBTL1TDP1KDM4EPOLBUGCG | |
| SCHEMBL22838215 | 0.88 | KDM4E (0.42) | L3MBTL1TDP1KDM4EPOLBUGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912993-B2 | Nucleic acid linked to a trivalent glycoconjugate | SILENCE THERAPEUTICS GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-11912993-B2 | Nucleic acid linked to a trivalent glycoconjugate | SILENCE THERAPEUTICS GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-20210079397-A1 | NUCLEIC ACID LINKED TO A TRIVALENT GLYCOCONJUGATE | SILENCE THERAPEUTICS GMBH (DE) | 2021-03-18 | — | — | US | disclosed |
| US-10913945-B2 | Nucleic acid linked to a trivalent glycoconjugate | SILENCE THERAPEUTICS GMBH (DE) | 2021-02-09 | — | — | US | disclosed |
| US-10913945-B2 | Nucleic acid linked to a trivalent glycoconjugate | SILENCE THERAPEUTICS GMBH (DE) | 2021-02-09 | — | — | US | disclosed |
| EP-3744350-A1 | NUCLEIC ACID LINKED TO A TRIVALENT GLYCOCONJUGATE | Silence Therapeutics GmbH (DE) | 2020-12-02 | — | — | EP | disclosed |
| EP-3439703-B1 | NUCLEIC ACID LINKED TO A TRIVALENT GLYCOCONJUGATE | SILENCE THERAPEUTICS GMBH (DE) | 2020-04-29 | — | — | EP | disclosed |
| EP-3439703-B1 | NUCLEIC ACID LINKED TO A TRIVALENT GLYCOCONJUGATE | SILENCE THERAPEUTICS GMBH (DE) | 2020-04-29 | — | — | EP | disclosed |
| US-20190119676-A1 | NUCLEIC ACID LINKED TO A TRIVALENT GLYCOCONJUGATE | SILENCE THERAPEUTICS GMBH (DE) | 2019-04-25 | — | — | US | disclosed |
| US-20190119676-A1 | NUCLEIC ACID LINKED TO A TRIVALENT GLYCOCONJUGATE | SILENCE THERAPEUTICS GMBH (DE) | 2019-04-25 | — | — | US | disclosed |
| EP-3439703-A1 | NUCLEIC ACID LINKED TO A TRIVALENT GLYCOCONJUGATE | Silence Therapeutics GmbH (DE) | 2019-02-13 | — | — | EP | disclosed |
| WO-2017174657-A1 | NUCLEIC ACID LINKED TO A TRIVALENT GLYCOCONJUGATE | SILENCE THERAPEUTICS GMBH (DE) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017174657-A1 | NUCLEIC ACID LINKED TO A TRIVALENT GLYCOCONJUGATE | SILENCE THERAPEUTICS GMBH (DE) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912993-B2 | Nucleic acid linked to a trivalent glycoconjugate | RNASE1, DERA, SNRPE | L3MBTL1 139/4885TDP1 1829/4885KDM4E 3203/4885 |
| US-10913945-B2 | Nucleic acid linked to a trivalent glycoconjugate | RNASE1, DERA, SNRPE | L3MBTL1 139/4885TDP1 1829/4885KDM4E 3203/4885 |
| US-20210079397-A1 | NUCLEIC ACID LINKED TO A TRIVALENT GLYCOCONJUGATE | RNASE1, DERA, SNRPE | L3MBTL1 139/4885TDP1 1829/4885KDM4E 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.